BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11134563)

  • 1. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity.
    Petz LD; Garratty G; Calhoun L; Clark BD; Terasaki PI; Gresens C; Gornbein JA; Landaw EM; Smith R; Cecka JM
    Transfusion; 2000 Dec; 40(12):1446-56. PubMed ID: 11134563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates.
    O'Connell BA; Lee EJ; Rothko K; Hussein MA; Schiffer CA
    Blood; 1992 Jan; 79(2):527-31. PubMed ID: 1730095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
    Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
    Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Filip DJ; Rodey GE; Rimm AA; Aster RH
    Am J Hematol; 1977; 2(3):219-26. PubMed ID: 596366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients.
    Friedberg RC; Donnelly SF; Mintz PD
    Transfusion; 1994 Mar; 34(3):215-20. PubMed ID: 8146893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet crossmatching. A direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient.
    Kickler TS; Ness PM; Braine HG
    Am J Clin Pathol; 1988 Jul; 90(1):69-72. PubMed ID: 3389345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
    Heal JM; Blumberg N; Masel D
    Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China.
    Xia WJ; Ye X; Tian LW; Xu XZ; Chen YK; Luo GP; Bei CH; Deng J; Santoso S; Fu YS
    Transfus Med; 2010 Aug; 20(4):269-74. PubMed ID: 20136782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful management of alloimmunized patients by transfusing HLA compatible and crossmatched platelets.
    Yung CH; Chow MP; Hu HY; Tzeng JL; Mou LL; Deng JM
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Apr; 47(4):228-36. PubMed ID: 1646671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening.
    Kreuger AL; Mäkelburg ABU; Somers JAE; Tomson B; van de Watering LMG; van der Bom JG; van Kraaij MGJ; Weller CM
    Transfusion; 2019 Nov; 59(11):3303-3307. PubMed ID: 31602653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience.
    Karlström C; Linjama T; Edgren G; Lauronen J; Wikman A; Höglund P
    Transfusion; 2019 Mar; 59(3):945-952. PubMed ID: 30575964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection.
    Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD
    JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience of HLA-matched platelet transfusion in patients who are refractory to random donor platelets].
    Sekiguchi S; Mitani T; Ohnuma M; Katoh T; Ikeda H; Nakase T; Morioka M; Sakurada K; Miyazaki T
    Hokkaido Igaku Zasshi; 1988 Jul; 63(4):552-61. PubMed ID: 3220437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion strategy: use of HLA-matched platelet transfusions for alloimmunized patients.
    Menitove JE; Duquesnoy RJ
    Am J Med Technol; 1981 Feb; 47(2):114-20. PubMed ID: 7223758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between donor-recipient lymphocytotoxicity and the transfusion response using HLA-matched platelet concentrates.
    Herzig RH; Terasaki PI; Trapani RJ; Herzig GP; Graw RG
    Transfusion; 1977; 17(6):657-61. PubMed ID: 595123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
    Sintnicolaas K; Löwenberg B
    Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
    Brubaker DB; Romine M
    Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR].
    Gao SQ; Xu YP; Luo CR; Li DC; Pen L; Liu T; Zou QC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):242-249. PubMed ID: 38387929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial.
    Marsh JC; Stanworth SJ; Pankhurst LA; Kallon D; Gilbertson AZ; Pigden C; Deary AJ; Mora AS; Brown J; Laing ES; Choo LL; Hodge R; Llewelyn CA; Harding K; Sage D; Mijovic A; Mufti GJ; Navarrete CV; Brown CJ
    Blood; 2021 Jan; 137(3):310-322. PubMed ID: 33475737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.